Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer Meeting Abstract
| Authors: | Shen, S.; Safonov, A.; Bromberg, M.; Chen, Y.; Ahmed, M.; Razavi, P.; Jhaveri, K. L. |
| Abstract Title: | Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400166 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1057 |
| Notes: | Meeting Abstract: 1057 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
